Cell No. : Cell Name
RCB1724 : JHSK-rec update : 2023/01/04 |
||||
Comment | Human cell line derived from rectal cancer. Application consideration | |||
Comment from the depositor | ||||
Terms and conditions | A prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use. | |||
Remarks | ||||
approver's address |
×
|
|||
Order Form | Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)   | |||
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp). | ||||
Basic information | Depositor | Ishikawa, Hiroshi | ||
Originator | Ishikawa, Hiroshi & Tabei, Isao | |||
Year of deposit | 2001 | |||
Animal | _human < Mammals | |||
Genus | Homo | |||
Species | sapiens | |||
Race | Japanese | |||
Gender | Male | |||
Age at sampling | 65 years | |||
Tissue | rectum | |||
Classification | cancer | |||
Year of origin | 2000 | Lifespan | infinite | |
Morphology | epithelial-like | |||
Cellosaurus(Expasy) | CVCL_6661 | |||
Medium | Medium List | Culture type | Adherent cells | |
Culture medium | DMEM/HamF12 + 10% FBS + 0.1mM NEAA | |||
Antibiotics | Free | Passage method | (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA) | Culture information | Passage ratio | 1 : 4 split |
SC frequency | Subculture : once/week, Medium Renewal : 2 times/week | |||
Temperature | 37 ℃ | |||
CO2 concentration | 5 % | |||
Freeze medium | Medium + 10% DMSO | |||
Freezing method | Slow freezing | |||
Mycoplasma/Acholeplasma | (-) | |||
Isozyme | LD, NP | |||
STR(human) | OK | |||
Reference information | Reference | 0 | ||
User's Publication | 2 | |||
Reference |